Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Ozaki Y, et al. Among authors: ichihara e. Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y. Epub 2024 Mar 25. Int J Clin Oncol. 2024. PMID: 38526621
Early palliative care in non-small-cell lung cancer.
Ichihara E, Matsuoka J, Kiura K. Ichihara E, et al. N Engl J Med. 2010 Dec 2;363(23):2263; author reply 2264-5. doi: 10.1056/NEJMc1010529. N Engl J Med. 2010. PMID: 21121847 No abstract available.
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. Hrustanovic G, et al. Among authors: ichihara e. Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24. Nat Med. 2015. PMID: 26301689 Free PMC article.
Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Saito K, Takigawa N, Ohtani N, Iioka H, Tomita Y, Ueda R, Fukuoka J, Kuwahara K, Ichihara E, Kiura K, Kondo E. Saito K, et al. Among authors: ichihara e. Mol Cancer Ther. 2013 Aug;12(8):1616-28. doi: 10.1158/1535-7163.MCT-12-1239. Epub 2013 Jun 12. Mol Cancer Ther. 2013. PMID: 23761220
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. Konduri K, et al. Among authors: ichihara e. Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21. Cancer Discov. 2016. PMID: 27102076 Free PMC article.
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K. Zhang D, et al. Among authors: ichihara e. Cancer Lett. 2011 Oct 28;309(2):228-35. doi: 10.1016/j.canlet.2011.06.006. Epub 2011 Jun 24. Cancer Lett. 2011. PMID: 21742432
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, Tanimoto M, Kiura K. Harada D, et al. Among authors: ichihara e. Cancer Sci. 2012 Oct;103(10):1795-802. doi: 10.1111/j.1349-7006.2012.02363.x. Epub 2012 Jul 24. Cancer Sci. 2012. PMID: 22712764 Free PMC article.
173 results